Kadcyla is contraindicated in patients with a history of hypersensitivity to trastuzumab or any of its components. It is also not recommended for use during pregnancy due to the potential for serious harm to the fetus. Women of childbearing potential should use effective contraception during treatment and for seven months after the last dose.
